At the virtual 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, important advances and potentially practice-changing trial data were presented in a range of gastrointestinal (GI) malignancies such as esophageal, gastric and colorectal cancer. VJOncology has assembled an esteemed panel of leading GI experts to discuss the latest exciting developments, what these advances could actually mean for clinical practice in the future and what still needs to be done.

Tobias Arkenau, MD, PHD, Sarah Cannon Research Institute UK, London, UK, chairs this roundtable discussion and is joined by:

• Deborah Mukherji, MBBS, FRCP, American University of Beirut Medical Center, Beirut, Lebanon
• Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK
• Lizzy Smyth, MD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
• Nataliya Uboha, MD, PhD, University of Wisconsin, Madison, WI
• Susanna Ulahannan, MD, MMEd, University of Oklahoma, Oklahoma City, OK.

In this GI Cancer Session podcast, you will learn about the results of  the CheckMate 648 and RATIONALE 302 trials in esophageal cancer, as well as key gastric cancer studies, including KEYNOTE-811 and MAHOGANY. The panel also offer their perspectives on the study of first-line FOLFOXIRI plus cetuximab or bevacizumab in patients with RAS wild-type metastatic colorectal cancer in the DEEPER trial, and colorectal cancer maintenance therapy in the PanaMa and FOCUS4 trials. The panel also consider the use of Nal-IRI in biliary tract and pancreatic cancers, as well as promising data on emerging therapies such as trastuzumab deruxtecan, an anti-HER2 antibody-drug-conjugate, in metastatic colorectal cancer from the DESTINY-CRC01 trial.